rs1344266804
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PM2PM3_SupportingPP4
This summary comes from the ClinGen Evidence Repository: The NM_000152.5:c.2407C>T (p.Gln803Ter) variant in GAA is a nonsense variant predicted to cause a premature stop codon in biologically-relevant-exon 17 (out of 20 exons), leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). One patient with late onset Pompe disease with this variant and treated by enzyme replacement therapy has been reported (PP4). This individual is compound heterozygous for the variant and "IVS 0-45T>G" (assumed to be c.-32-13T>G), a pathogenic variant in GAA, phase unknown (PMID:26572913) (PM3_Supporting). Two additional patients have been reported to be compound heterozygous for p.Gln803Ter but the cDNA change provided is incorrect and thus this data was not included (PMID:21940687). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00001 (1/111412 alleles) in the European-Non-Finnish population, which is lower than the ClinGen Lysosomal Diseases VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion. There is a ClinVar entry for this variant (Variation ID: 552368). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): PVS1, PP4, PM2_Supporting, PM3_Supporting.(Classification approved by the ClinGen Lysosomal Diseases VCEP, July 3, 2023) LINK:https://erepo.genome.network/evrepo/ui/classification/CA401325116/MONDO:0009290/010
Frequency
Consequence
NM_000152.5 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152210Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000402 AC: 1AN: 248496Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135010
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1460416Hom.: 0 Cov.: 35 AF XY: 0.00000138 AC XY: 1AN XY: 726516
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152210Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74360
ClinVar
Submissions by phenotype
Glycogen storage disease, type II Pathogenic:4
- -
This sequence change creates a premature translational stop signal (p.Gln803*) in the GAA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GAA are known to be pathogenic (PMID: 18425781, 22252923). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with Pompe disease (PMID: 26572913). ClinVar contains an entry for this variant (Variation ID: 552368). For these reasons, this variant has been classified as Pathogenic. -
- -
The NM_000152.5:c.2407C>T (p.Gln803Ter) variant in GAA is a nonsense variant predicted to cause a premature stop codon in biologically-relevant-exon 17 (out of 20 exons), leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). One patient with late onset Pompe disease with this variant and treated by enzyme replacement therapy has been reported (PP4). This individual is compound heterozygous for the variant and "IVS 0-45T>G" (assumed to be c.-32-13T>G), a pathogenic variant in GAA, phase unknown (PMID: 26572913) (PM3_Supporting). Two additional patients have been reported to be compound heterozygous for p.Gln803Ter but the cDNA change provided is incorrect and thus this data was not included (PMID: 21940687). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00001 (1/111412 alleles) in the European-Non-Finnish population, which is lower than the ClinGen Lysosomal Diseases VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion. There is a ClinVar entry for this variant (Variation ID: 552368). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): PVS1, PP4, PM2_Supporting, PM3_Supporting. (Classification approved by the ClinGen Lysosomal Diseases VCEP, July 3, 2023) -
not provided Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at